Results 191 to 200 of about 17,663 (255)

Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. [PDF]

Eur Heart J Suppl, 2022
Fanaroff AC, Vora AN, Lopes RD.
europepmc   +1 more source

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in low-weight patients with atrial fibrillation. [PDF]

J Thromb Thrombolysis
Chen KH, Hsu YY, Chou CY, Hsu CC, Chang SL, Yu WC, Chang YL.   +6 more
europepmc   +1 more source

Safety and efficacy of non-vitamin K antagonist oral anticoagulants compared with well-controlled warfarin in Thai patients with atrial fibrillation. [PDF]

Asian Biomed (Res Rev News), 2022
Yamkasikorn J, Methavigul K.
europepmc   +1 more source

Erratum to: Worldwide trends in antithrombotic therapy prescribing for atrial fibrillation: observations on the 'transition era' to non-vitamin K antagonist oral anticoagulants. [PDF]

Europace, 2023
europepmc   +1 more source

Evaluation of Treatment Adjustments and the Impact of Non-Vitamin K Antagonist Oral Anticoagulants on Complications in Patients Undergoing Diagnostic Bronchoscopy.

Respiration
Malovrh MM, Bitežnik B, Adamič K, Rozman A.   +3 more
europepmc   +1 more source

Impact of insurance coverage for non-vitamin K antagonist oral anticoagulants on quality of care and care disparities in patients hospitalised with atrial fibrillation in tertiary hospitals in China: interrupted time series analysis. [PDF]

BMJ Open
Yang N, Sun Z, Liu J, Hao Y, Long D, Zhao D, Liu J, CCC-AF Investigators.   +7 more
europepmc   +1 more source

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. [PDF]

Cochrane Database Syst Rev
Al Said S, Kaier K, Sumaya W, Alsaid D, Duerschmied D, Storey RF, Gibson CM, Westermann D, Alabed S.   +8 more
europepmc   +1 more source

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of CardiologyWorking Group on Cardiovascular Pharmacotherapy and European Society of CardiologyWorking Group on Thrombosis [PDF]

, 2015
Agewall, Stefan, Atar, Dan, Drexel, Heinz, Elkjær Husted, Steen, Kaski, Juan, Kjeldsen, Keld, Koller, Lorenz, Lewis, Basil, Lip, Gregory, Morais, João, Niessner, Alexander, Storey, Robert, Tamargo, Juan, Torp-Pedersen, Christian, Verheugt, Freek, Wassmann, Sven   +15 more
core   +1 more source

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared with Vitamin K Antagonists in Patients with Atrial Fibrillation and Type 2 Valvular Heart Disease: A Systematic Review and Meta-Analysis. [PDF]

Cardiovasc Drugs Ther
Liang X, Liu S, Ji L, Ma F, Song G, Li F, Liu G.   +6 more
europepmc   +1 more source

Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study. [PDF]

Eur Heart J Qual Care Clin Outcomes
Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L.   +4 more
europepmc   +1 more source